Proportion of Patients in the United States Who Fill Their Nirmatrelvir/Ritonavir Prescriptions.

ABSTRACT:

Introduction

Although real-world studies demonstrate that those prescribed nirmatrelvir/ritonavir (and particularly within 5 days of symptom onset) are less likely to experience severe COVID-19 outcomes, prior studies show that only a small fraction of patients with COVID-19 who are eligible for nirmatrelvir/ritonavir receive a prescription. Studies calculating the proportion of nirmatrelvir/ritonavir prescriptions filled and identifying individual- and pharmacy-level correlates of filling nirmatrelvir/ritonavir are lacking.

Methods

This retrospective cohort study included individuals aged ≥ 12 years with a nirmatrelvir/ritonavir prescription ordered at a large national retail pharmacy (December 22, 2021-August 12, 2023). Those taking contraindicated medications were exclude

SUBMITTER: Rudolph AE 

PROVIDER: S-EPMC11343940 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature